Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Peer-reviewed paperarXiv

Empirical Stability Analysis of Kolmogorov-Arnold Networks in Hard-Constrained Recurrent Physics-Informed Discovery

View original at arxiv.org
{ "id": "2602.09988v1", "url": "http://arxiv.org/abs/2602.09988v1", "title": "Empirical Stability Analysis of Kolmogorov-Arnold Networks in Hard-Constrained Recurrent Physics-Informed Discovery", "summary": "We investigate the integration of Kolmogorov-Arnold Networks (KANs) into hard-constrained recurrent physics-info…
Opening lines of the source · arXiv · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A shallow KAN can exactly represent any univariate polynomial with sufficient spline resolution

    80% confidence
  • Empirical challenges highlight limitations of the additive inductive bias in the original KAN formulation for state coupling

    80% confidence
  • Small KANs are competitive on univariate polynomial residuals but exhibit severe hyperparameter fragility, instability in deeper configurations, and consistent failure on multiplicative terms

    80% confidence
  • KANs would enable efficient recovery of unknown terms compared to MLPs in hard-constrained recurrent physics-informed architectures

    80% confidence
  • The primary bottleneck in recurrent KAN integration is the optimization stability of the composition, not the symbolic extraction process itself

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com